title: Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.
abstract: The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and steroid receptor positive breast cancer patients. Two hundred and five tumour samples from a randomised clinical trial of 596 lymph node- and steroid receptor positive breast cancer patients were included. All patients had been randomly allocated to receive 20 mg of adjuvant tamoxifen (TAM) daily for 2 years or TAM plus one cycle of low-dose, short-term chemotherapy. For detection of p53 mutations we used in vitro amplification by polymerase chain reaction and consecutively performed temperature gradient gel electrophoresis (PCR-TGGE) and direct sequencing. We found p53 mutations in 42/205 (20%) cases: 16/42 (38%) p53 mutations occurred within the L2/L3 domains of the p53 gene, and 26/42 (62%) outside the L2/L3 domains. p53 mutation served as a statistically significant parameter in predicting disease-free survival in univariate (P = 0.02) and multivariate (P = 0.009) analysis. For overall survival, no significant differences were observed. Patients with tumours that had p53 mutations within the L2/L3 domains of the gene showed no significant difference to those with mutations outside the L2/L3 domains for disease-free survival. For overall survival, mutations in the L2/L3 domains showed a marginally significant difference (P = 0.05) in multivariate analysis, but not in univariate analysis (P = 0.13). We conclude that mutation in the L2/L3 domains of the p53 gene is not an independent prognostic indicator of disease outcome for patients suffering from breast cancer with lymph node metastases and positive steroid receptors.
authors.affiliation: Department of Gynaecology and Obstetrics, University of Vienna Medical School, Austria. elisabeth.kucera@akh-wien.ac.at
authors.forename: E
authors.initials: E
authors.lastname: Kucera
authors.forename: P
authors.initials: P
authors.lastname: Speiser
authors.forename: M
authors.initials: M
authors.lastname: Gnant
authors.forename: L
authors.initials: L
authors.lastname: Szabo
authors.forename: H
authors.initials: H
authors.lastname: Samonigg
authors.forename: H
authors.initials: H
authors.lastname: Hausmaninger
authors.forename: M
authors.initials: M
authors.lastname: Mittlböck
authors.forename: M
authors.initials: M
authors.lastname: Fridrik
authors.forename: M
authors.initials: M
authors.lastname: Seifert
authors.forename: E
authors.initials: E
authors.lastname: Kubista
authors.forename: A
authors.initials: A
authors.lastname: Reiner
authors.forename: R
authors.initials: R
authors.lastname: Zeillinger
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D011987:Receptors, Steroid / Q000378:metabolism; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D015032:Zinc / Q000378:metabolism
chemical_list: D011987:Receptors, Steroid; D013629:Tamoxifen; D015032:Zinc